EM1903G "Clonal Hematopoiesis: A Recently-Described Clinical Entity that is Very Common and Has Major Clinical Consequences" (IM GR-030119)
The purpose of this lecture is to provide an overview of the recently described clinical entity, clonal hematopoiesis, in terms of its discovery, pathogenesis, clinical presentation, management, and future research directions.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Understand the concepts of normal and clonal hematopoiesis
- Understand the frequency and degree of clonal hematopoiesis in the older population.
- Understand the clinical consequences of clonal hematopoiesis in terms of increased risk of blood malignancy and atherosclerotic cardiovascular disease.
- Understand the different ways that clonal hematopoiesis can present in the clinic.
- Understand the pathogenesis of the disorder and potential future directions in management.
Robert Collins, M.D., FACP
Director, Hematologic Malignancies/Blood and Marrow Transplant Program
Professor, Department of Internal Medicine
Division of Hematology/Oncology
Dr.Collins is a Professor of Internal Medicine in the Division of Hematology/Oncology. He is the Director of the Hematologic Malignancies/Blood and Marrow Transplant Program. His research interests include immunology of stem cell transplantation and experimental therapeutics for hematologic malignancies.
- 1.00 AMA